Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
|
27649927 |
2017 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activating mutations of the NRAS (neuroblastoma rat sarcoma viral oncogene) protein kinase, present in many cancers, induce a constitutive activation of both the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signal transduction pathway and the PI(3)K-AKT-mTOR, pathway.
|
27533468 |
2016 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activation of PI3K/AKT survival pathway may contribute to the increased drug resistance in TrkB-expressing neuroblastomas.
|
12438236 |
2002 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activation of PI3K/Akt/mTOR signaling pathway correlates with oncogenesis, poor prognosis and chemotherapy resistance in NB.
|
29499203 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
|
31310053 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autophagy markers were also measured in cypermethrin-treated neuroblastoma cells in the presence of 3-methyl adenine, a phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) class III inhibitor; vinblastine, an autophagosome elongation inhibitor; bafilomycin A1, an autophagolysosome and lysosome fusion/abnormal acidification inhibitor or torin 1, a mechanistic target of rapamycin inhibitor.
|
28840510 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both MAPK and PI3K pathways were involved in BDNF protection of NB cells from paclitaxel-induced cell death, while PI3K predominantly mediated BDNF protection of NB cells from etoposide or cisplatin-induced cell death.
|
16778834 |
2007 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistent with these observations, PI3K inhibition in MYCN-amplified human neuroblastoma cell lines resulted in decreased levels of Mycn protein without affecting levels of MYCN mRNA and caused decreased proliferation and increased apoptosis.
|
16912192 |
2006 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of the expression of these PI3K genes can predict aggressive disease, and indicates stage-dependent involvement of PI3K-pathway members in neuroblastoma.
|
23232578 |
2013 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For this reason, the present study investigated the presence of such mutations in neuroblastomas (NBs) and tested NB cell lines for sensitivity to FGFR and phosphoinositide 3‑kinase (PI3K) inhibitors.
|
31638167 |
2019 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we demonstrate that PI3K/Akt pathway is crucial for the upregulation of P2X7R expression in serum-deprived neuroblastoma cells, circumstance that facilitates cell proliferation in the absence of trophic support.
|
26687764 |
2015 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that p37δ, a kinase-dead isoform of the PI3K catalytic subunit p110δ, is over-expressed in neuroblastoma tumors, and that it correlates with the activation of both PI3K/Akt- and RAS-signaling pathways.
|
24026661 |
2013 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, NVP-BEZ235, a potent dual PI3K and mTOR inhibitor have not shown beneficial effects on neuroblastoma especially in terms of apoptosis induction as a single agent.
|
27278249 |
2016 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, cell proliferation via the GFRA2-PTEN-PI3K/AKT axis may represent new target to develop treatments for neuroblastoma.
|
30722993 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, we found NLGN3 promoted neuroblastoma cell proliferation and growth through activating PI3K/AKT pathway and providing a new target for neuroblastoma therapy.
|
31150649 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we investigated the phosphorylation status of key proteins in the PI3K/AKT/mTOR pathway and the effects of the mTOR inhibitors rapamycin and CCI-779 on neuroblastoma tumorigenesis.
|
18026138 |
2008 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of the PI3K/Akt pathway does not increase the sensitivity of neuroblastoma cell lines to TRAIL-induced apoptosis.
|
16769337 |
2006 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
|
25228590 |
2014 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, inhibitors of PI3K/mTOR and GLI signaling reduced neuroblastoma cell growth, but no additional growth inhibitory effects were detected when the two classes of drugs were combined.
|
25134527 |
2014 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neuroprotection of miR-214 against isoflurane-induced neurotoxicity involves the PTEN/PI3K/Akt pathway in human neuroblastoma cell line SH-SY5Y.
|
31704096 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data also suggest that the phosphoinositide 3-kinase (PI3K) inhibitors may provide new opportunities for the treatment of the <i>MYCN</i>-amplified neuroblastoma subtype.
|
29137381 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous studies have demonstrated that PI3K/AKT signaling is critical for the oncogenic transformations induced by gastrin-releasing peptide (GRP) and its receptor, GRP-R, in neuroblastoma.
|
23468863 |
2013 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that targeting PI3K and mTORC2 in aggressive neuroblastomas with an immature phenotype may improve therapeutic efficacy.
|
26432405 |
2015 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palmitic acid stimulates energy metabolism and inhibits insulin/PI3K/AKT signaling in differentiated human neuroblastoma cells: The role of mTOR activation and mitochondrial ROS production.
|
28919254 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological inhibition of PI3K greatly reduced the ability of PDGF-BB to block gp120 IIIB-mediated apoptosis and cell death in human neuroblastoma cells.
|
18973553 |
2008 |